Conventional IgA nephropathy treatments include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. The only two FDA-approved treatments for managing IgAN are TARPEYO/KINPEYGO (budesonide) and FILSPARI (sparsentan). Before TARPEYO’s launch, its price level was a potential concern. However, TARPEYO has been successfully introduced at a premium price and has increased its price twice, once in early 2023 and again in early 2024.
Travere’s FILSPARI received conditional approval in February 2023. At this early stage, interest levels are moderate, as indicated by initial ...
